and CNS Treatments
A Better, Safer, Targeted Universal Delivery
1 in 6 of the world’s population suffers from neurological disorders
Nextar's novel platform brings new hope to patients suffering from neurological disorders and diseases
The Blood-Brain Barrier (BBB) is a highly selective mechanism protecting the brain from foreign agents by preventing ~95% of the molecules in the blood from entering the brain.
The BBB's extremely low permeability presents a significant challenge to drug therapies targeting the brain and the Central Nervous System (CNS). Currently, most of these treatments require the administration of high doses as only a low concentration of the administered dosage finds its way into the brain. Drug molecules that fail to penetrate the brain get systemically dispersed and may cause severe side effects.
Our platform provides a solution for the targeted delivery of drugs into the brain that can improve the lives of 1.25 billion people suffering from medical conditions related to the brain and the CNS.
Our Brain Targeted Liposomes (BTLs) Platform
Nextar's proprietary Brain Targeted Liposomes (BTLs) platform, can facilitate targeted delivery of versatile drugs across the BBB and into the brain. The innovative drug delivery platform is a combination of a liposomal vehicle with the unique Targeter complex that allows BBB permeation and brain-specific delivery of versatile therapeutic agents.
The incidence of brain and central nervous system diseases in all ages increases and is now the second leading cause of death globally. There is an urgent need for a solution for a safe, efficient administration of drugs for CNS treatment.
Nextar's platform is applicable for different drug candidates in CNS, neurodegenerative diseases, and brain cancers. Pre-clinical proof of concept was demonstrated with promising results showing a substantial efficacy in Glioblastoma and Parkinson’s animal models.
Our platform's advantages
Targeted and specific delivery of drug-loaded nano-particles
Broad application potential Can encapsulate hydrophilic and hydrophobic molecules
Safe No disruption of BBB function and only biodegradable components.
Encapsulation using non-
covalent bonds molecules
Limited off target effects negligible dissipation to areas outside the brain shown in animal models
Cost-efficient process for adapting
the platform for new drugs and preparing it for commercialization.